OSI TO CLOSE EYETECH DEAL

OSI Pharmaceuticals eased the worries of Eyetech's shareholders by saying it will in fact close its acquisition of the eye-disease drugmaker on Monday. Last Thursday, OSI rattled Eyetech investors by saying that before it would complete the purchase, it wanted to assess data from Genentech for the drug Lucentis -- a potential competitor to Eyetech's only commercial product, Macugen.

The Street (http://www.thestreet.com/_googlen/stocks/biotech/10252701.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA)